Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."
On June 19, 2020, Glenmark became the first company in India to receive restricted emergency use approval from India's drug regulator for Favipiravir (FabiFlu).
Glenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.
Glenmark Life Sciences IPO Allotment status, Glenmark IPO GMP today: Glenmark Life Sciences IPO allotment status has been finalised. Glenmark IPO allotment status is available on KFintech's website. Glenmark Life Sciences shares will be listed on the BSE and NSE on August 6.
Glenmark Life Sciences IPO Allotment, Glenmark Life Sciences IPO GMP Latest: Glenmark Life Sciences IPO allotment status will be available on the website of KFintech.
Glenmark IPO Allotment Date, Glenmark Life Sciences IPO GMP: Glenmark Life Sciences is a subsidiary of Glenmark Pharmaceuticals. Glenmark Life Sciences IPO listing date is August 6.
Glenmark Life Sciences IPO, Glenmark Life Sciences GMP: Glenmark Life Sciences IPO is open for subscription. The grey market premium is currently at 20 per cent premium.
Glenmark Life Sciences IPO: Glenmark Life Sciences on Monday said it has raised Rs 454 crore from anchor investors ahead of its initial share sale, which opens for public subscription on Tuesday.
The public issue will have a fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma.
Glenmark Life Sciences IPO: The initial public offer (IPO) of Glenmark Life Sciences will open for subscription on July 27 and close on July 29, 2021. Glenmark Life Sciences is the API (active pharmaceutical ingredients) arm of Glenmark Pharmaceuticals.
Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems
Shares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.
Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.
Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Tacrolimus capsules, used as immuno-suppressant.
Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market Sirolimus tablets, an immunosuppressant, in the American market.
Glenmark Pharma on Wednesday announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India.
Glenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
According to Glenmark, 40 per cent faster achievement of "clinical cure" was witnessed in the third phase of the clinical trials of Favipiravir involving 150 patients with mild to moderate COVID-19 across seven clinical sites in India.
Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19.
Shares of Glenmark Pharmaceuticals on Monday tumbled nearly 6 per cent after India's drug regulator sought clarification from the company over its alleged "false claims" about the use of anti-viral FabiFlu on COVID-19 patients with comorbidities and also over the "pricing" of the drug.
Top News
Latest News
